Curis Q2 2025 net loss $8.6M; cash runway extended to Q1 2026 via $6M offering

CURIS INC

2025-Q2 EPS reported -$1.82 vs consensus -$0.91 ▼ miss (-100.5%)

Net loss $8.6M ($0.68/sh) vs $11.8M ($2.03/sh) in Q2 2024; revenue $2.7M from Erivedge royalties.
Cash and equivalents $10.1M at June 30, 2025; July 2025 offerings added ~$6M net proceeds.
TakeAim Lymphoma study enrolling PCNSL patients to support US/EU accelerated approval; data expected later 2025.
Adding proof-of-concept CLL study of emavusertib + BTKi in 20-30 R/R patients; enrollment to begin later 2025.
TakeAim Leukemia Phase 1/2 enrollment complete; designing registrational trial vs gilteritinib in R/R AML.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.